Analysts have recently evaluated Alkermes and provided 12-month price targets. The average target is $42.17, accompanied by a ...

UBS upgraded Alkermes (NASDAQ:ALKS) to Buy from Neutral on Tuesday, citing prospects for Irish biotech’s orexin 2 receptor ...

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Alkermes plc (NASDAQ:ALKS) as an investment opportunity by projecting its future cash flows and ...

AlkermesALKS saw a positive improvement to its Relative Strength (RS) Rating on Monday, rising from 65 to 72. Please watch ...

Google’s new ‘G’ logo appeared on stage during the I/O 2025 keynote, and is now live in more apps and the web. The new logo made its debut with the Google app on Android and iOS last week.

Alkermes is facing a significant delay for its ALKS 5461 candidate for major depressive disorder after the FDA turned down its marketing application. The negative outcome for the review isn’t ...

The meetings included: "Alkermes is honored to present at these notable scientific meetings, sharing our research and insights with thought leaders and healthcare providers from across the field ...

There's little doubt these pharmaceutical companies' costs will soon be rising at least a little. The tariff war the U.S. is waging against most of the world stabilized somewhat earlier this month.

"Alkermes is honored to present at these notable scientific meetings, sharing our research and insights with thought leaders and healthcare providers from across the field of psychiatry," said ...

Pharmaceutical manufacturing encompasses all processes involved in the manufacturing and production of biological and medical products, botanical drugs, and herbs, as well as other pharmaceutical ...

Alkermes has agreed a $950 million deal to acquire Rodin Therapeutics, a US biotech developing drugs for neurodegenerative diseases. Dublin-headquartered Alkermes is paying $100 million upfront to ...

Logo: https://mma.prnewswire.com/media/1713483/Galmed_Pharmaceuticals_Logo.jpg View original content:https://www.prnewswire.com/news-releases/galmed-pharmaceuticals ...